Osteonic Q1 2026 Results: Revenue 12.9B, Operating Profit 2.3B, Return to Profitability
-
Consolidated revenue 12.9B KRW (up 35% YoY), operating profit 2.3B, net profit 2.7B (3x increase)
-
Eliminated accumulated deficit, retained earnings turned positive to 2.1B (from -0.5B at year-end)
-
Bio-material (Sports Medicine) segment led growth at 43.5% of sales
-
R&D expense 1.38B (6.2% of revenue)
-
Secured 3.9B facility loan from KDB (maturity 2029, interest 2.64%)
-
Extraordinary general meeting scheduled for June 26, 2026
KOSDAQ Filing Information
-
Filing: Quarterly Report (2026.03)
-
Company: OSTEONIC (226400)
-
Submission: OSTEONIC Co., Ltd.
-
Receipt: 05-14-2026